Post-Termination Activities. Executive acknowledges and agrees that, during the course of his employment with the Company, he had access to the Company’s Proprietary, Trade Secret and Confidential Information, and that disclosure to or use of such information by a competitor of the Company would cause the Company irreparable harm. Executive agrees and acknowledges that should he engage in the restricted activities as set forth in Section 5 hereof, he will inevitably disclose the Company’s Proprietary, Trade Secret and Confidential Information.
Post-Termination Activities. (a) Each Party will render a post-termination report as required by Sections 4.11, 9.1, and 9.2 within the period specified in such provisions after the date of termination or expiration of this Agreement. Each Party will be entitled to conduct one audit in accordance with Section 9.9 within ninety (90) days after the date of termination or expiration. To the extent surviving termination, each Party will continue to comply with the terms of all licenses granted to it in accordance with Section 10.14.
Post-Termination Activities. (a) The Executive agrees that during his/her employment with the Company and for 12 months thereafter, the Executive will not, and will not cause others to:
Post-Termination Activities. Upon termination of this Agreement CRISPR shall provide CureVac with a written inventory of all Licensed Products that are in the process of Manufacture, in use or in stock; provided, however, that if CRISPR terminates this Agreement in part under Section 13.3, such inventory shall only apply to the Licensed Products subject to such partial termination. All Licensed Products that are not disposed of as provided above shall be delivered to CureVac or otherwise disposed of in CureVac’s sole discretion and at CRISPR’s sole expense.
Post-Termination Activities. In the event that either Party issues a notice of termination of this Agreement, the Parties will exercise Commercially Reasonable Efforts during the [***] period following issuance by a Party of such notice of termination to reach agreement regarding an appropriate wind-down plan, taking into account ethical responsibilities to patients in clinical trials (if any), control of any trailing project costs, and the stewardship of intellectual property and other assets created by the Parties hereunder. Battelle shall promptly transfer or return to Discovery Labs all data, reports, materials, Discovery Labs Inventions, designs, models, working embodiments, prototypes etc. of the device, and must take continuing action to disclose and transfer the know-how and technical information relating to the Project to Discovery Labs and to cooperate and take measures to assign to Discovery Labs and execute such documents as Discovery Labs may reasonably request to perfect Discovery Labs’ title as sole owner of all Discovery Labs’ Inventions. Except as provided in Section 5.D(i), Discovery Labs shall pay Battelle’s reasonable expenses in complying with this Section 5.F. Battelle shall issue to Discovery Labs detailed invoices in a manner consistent with those prepared for Stage 1 Work described in Section 3.A.
Post-Termination Activities. (i) Xxxxxxx will, at Licensor’s election, wind down, complete or transfer to Licensor any Research or Development activity relating to the Reverted Products that is ongoing on the Termination CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS HAVE BEEN MADE. Effective Date. If Licensor fails to make an election prior to the Termination Effective Date, then Licensor will be deemed to have elected to have Xxxxxxx wind down the applicable activity. Xxxxxxx will bear any costs incurred in winding down any such activity [***]. Licensor will reimburse Xxxxxxx for any costs incurred after the Termination Effective Date to complete or transfer any activity.
Post-Termination Activities. (i) Xxxxxxx will, at Licensor’s election, wind down, complete or transfer to Licensor any Research or Development activity relating to the Reverted Products that is ongoing on the Termination Effective Date. If Licensor fails to make an election prior to the Termination Effective Date, then Licensor will be deemed to have elected to have Xxxxxxx wind down the applicable activity. Xxxxxxx will bear any costs incurred in winding down any such activity (unless Licensor has exercised its Co-Funding Option and the provisions of Section 4.8 have not been terminated in accordance with Section 4.8.2(b)(v) or Section 4.8.3, in which case they shall be shared by the Parties as Shared Development Costs to the extent applicable). Licensor will reimburse Xxxxxxx for any costs incurred after the Termination Effective Date to complete or transfer any activity.
Post-Termination Activities. Upon termination of this Agreement pursuant to Section 10.2(a) hereof, each of CAI, CAHS and CHCM agrees, jointly and severally, as follows:
Post-Termination Activities. 16.1.1 Upon termination of the rights and licenses granted to MedImmune in its entirety, and subject to any rights retained by MedImmune’s sublicensees in the Territory pursuant to Section 16.7, Micromet will have the right to continue the development of and to Commercialize Licensed Product by itself or with or through Third Parties anywhere in the world. Upon such termination, MedImmune will upon request of Micromet:
Post-Termination Activities. After the cessation of your employment for any reason, neither party shall (a) represent itself as having any on-going relationship with the other, (b) make or cause to be made (whether directly or indirectly) any derogatory comments or statements about the you or the Firm or its officers or employees, as applicable and (c) make, or cause to be made (whether directly or indirectly), any statement or comment to the press or other media concerning your employment or termination of employment with the Firm or your termination or resignation from any directorships or other offices with the Firm, without the prior written consent of the other party except in the case of the Company as necessary to comply with applicable law or the rules of the New York Stock Exchange or any other stock exchange on which the Company’s stock may be traded (and any public statements made in good faith by the Company in connection therewith).
